Takeda Type II diabetes drug shown useful in late-stage trial

09/13/2005 | Wall Street Journal, The

Researchers report that Takeda Pharmaceuticals' Actos proved effective in a late-stage trial in reducing the risk of fatal or serious conditions associated with Type II diabetes. In conjunction with Eli Lilly, Takeda has been developing the drug, which the companies said reduced the combined risk of heart attacks, strokes and death by 16%.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL